Bicara Therapeutics Inc. (BCAX)
NASDAQ: BCAX · Real-Time Price · USD
27.73
-0.33 (-1.18%)
Aug 10, 2026, 4:00 PM EDT - Market closed
Bicara Therapeutics Employees
Bicara Therapeutics had 103 employees as of December 31, 2025. The number of employees increased by 48 or 87.27% compared to the previous year.
Employees
103
Change (1Y)
48
Growth (1Y)
87.27%
Revenue / Employee
n/a
Profits / Employee
-$1,527,330
Market Cap
1.82B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 103 | 48 | 87.27% |
| Dec 31, 2024 | 55 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Recursion Pharmaceuticals | 600 |
| Agios Pharmaceuticals | 540 |
| Lakefront Biotherapeutics NV | 452 |
| Syndax Pharmaceuticals | 298 |
| Kardigan | 241 |
| Septerna | 130 |
| Forte Biosciences | 22 |
BCAX News
- 6 days ago - Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET - GlobeNewsWire
- 13 days ago - Bicara Therapeutics Announces Appointments of Jeremy Bender and Christy Oliger to Board of Directors - GlobeNewsWire
- 5 weeks ago - Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Bicara Therapeutics Transcript: Study update - Transcripts
- 2 months ago - Bicara Therapeutics Press release: Study update - Filings
- 2 months ago - Bicara Therapeutics Slides: Study update - Filings
- 2 months ago - Bicara Therapeutics management to meet with Cantor - TheFly
- 2 months ago - Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC - GlobeNewsWire